Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospec
- PDF / 437,763 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 55 Downloads / 177 Views
ORIGINAL ARTICLE
Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT Satoshi Yamasaki 1 & Jinichi Mori 2 & Junya Kanda 3 & Nobuhiko Imahashi 4 & Naoyuki Uchida 5 & Noriko Doki 6 & Masatsugu Tanaka 7 & Yuta Katayama 8 & Tetsuya Eto 9 & Yukiyasu Ozawa 10 & Satoru Takada 11 & Makoto Onizuka 12 & Masayuki Hino 13 & Yoshinobu Kanda 14 & Takahiro Fukuda 15 & Yoshiko Atsuta 16,17 & Masamitsu Yanada 18 Received: 5 July 2020 / Accepted: 7 September 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract This study aimed to analyze the factors associated with outcomes of bone marrow transplantation (UR-BMT) or cord blood stem cell transplantation from unrelated donors (UR-CBT). We assessed the time from diagnosis to transplantation among acute myeloid leukemia (AML) patients with intermediate- or poor-risk cytogenetics to identify the potential clinical efficacy of transplantation. We retrospectively analyzed 5331 patients who received UR-BMT or UR-CBT between 2008 and 2017. Patients were divided into four groups according to time from diagnosis to transplantation: (1) UR-BMT and > 5 months (n = 2353), (2) UR-BMT and ≤ 5 months (n = 379), (3) UR-CBT and > 5 months (n = 1494), and (4) UR-CBT and ≤ 5 months (n = 1106). There was no difference in overall survival (OS) for transplantation at ≤5 months and > 5 months in patients with first complete remission for both UR-BMT and UR-CBT, but OS in patients with primary induction failure (PIF) and transplantation at ≤ 5 months was significantly higher in the UR-CBT group compared with that at >5 months (P < 0.001). Multivariate Cox regression analysis also showed that transplantation at >5 months in patients with PIF was an independent predictor of poorer OS. Therefore, UR-CBT at ≤ 5 months after diagnosis is an alternative option for AML patients with PIF. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00277-020-04261-6) contains supplementary material, which is available to authorized users. * Satoshi Yamasaki [email protected] 1
Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
9
Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
10
Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
11
Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan
12
Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
2
Department of Hematology, Jyoban Hospital, Iwaki, Japan
3
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
4
13
Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
Department of Hematology, Osaka City University, Osaka, Japan
14
Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Tor
Data Loading...
